ProForma 2.0
validated simple linear
SLLMWITQC
Back to Primary literature
Primary-literature peptidehigh evidence PepDiana evidence grade for a literature-derived identity; Medium indicates retained review flags, while High has no unresolved review flag.
PEPDIA-PLP-002699
NY-ESO-1 157-165 epitope
Aliases: MAGE, NY-ESO-1, NY-ESO-1 157-165 epitope
Normalized sequence
SLLMWITQC
9 amino acids
Release PepDiana-V1-20260620
52
Activity records
2
Source papers
38
Positive
14
Negative / threshold
Versioned scientific descriptors
Physicochemical properties and standard representations
Reported properties
No separate physicochemical property was reported in the primary-literature identity record. PepDiana release values are shown as computed properties.
Computed properties
physchem-20260620Molecular weight
1094.3473 Da
Molecular formula
C49H79N11O13S2
Theoretical pI
5.2381
Net charge at pH 7
-0.5498
GRAVY
1.1778
Instability index
-7.8667
Aromaticity
0.1111
Topological polar surface area
395.46 Ų
cLogP
-1.5395
Hydrogen-bond donors
15
Hydrogen-bond acceptors
15
Rotatable bonds
34
Method: PepDiana sequence/structure descriptor pipeline
Tool: Biopython+RDKit · Biopython 1.85; RDKit 2024.09.6
Calculated: 2026-06-20T11:01:38.358971+00:00
Assumptions: ph=7; termini=free N-terminus and free C-terminus for simple linear peptides; stereochemistry=standard L-amino acids; smiles_length_limit=200
Sequence representations
HELM 2.0
validated simple linear
PEPTIDE1{S.L.L.M.W.I.T.Q.C}$$$$V2.0
Canonical SMILES
validated
CCC(C)C(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CCSC)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(N)CO)C(=O)NC(C(=O)NC(CCC(N)=O)C(=O)NC(CS)C(=O)O)C(C)O
Isomeric SMILES
validated
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)O)[C@@H](C)O
Paper-level observations
Experimental evidence grouped by activity
Immunomodulatory 52 records
PMC12474311
33 observationsImmunomodulatoryT-cell activationPositive observation
Record detail TCR-T cells showed the greatest functional avidity for T2 cells, with an EC50 of 0.004 μM (Section 3.3, Figure 3a).
- Measure
- EC50
- Value
- 0.004 μM
- Target
- T2
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail The functional avidity of COS-7-A*02:01 was lower than that of the T2 cells, with an EC50 of 0.036 μM (Section 3.3, Figure 3b).
- Measure
- EC50
- Value
- 0.036 μM
- Target
- COS-7-A*02:01
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail The EC50 values of functional avidity for A*02:03 ... were 0.995 μM (Section 3.3, Figure 3c).
- Measure
- EC50
- Value
- 0.995 μM
- Target
- COS-7-A*02:03
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail The EC50 values of functional avidity for A*02:05 ... were 0.188 μM (Section 3.3, Figure 3d).
- Measure
- EC50
- Value
- 0.188 μM
- Target
- COS-7-A*02:05
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail The EC50 values of functional avidity for A*02:06 ... were 0.351 μM (Section 3.3, Figure 3e).
- Measure
- EC50
- Value
- 0.351 μM
- Target
- COS-7-A*02:06
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail The EC50 values of functional avidity for A*02:10 were 0.239 μM (Section 3.3, Figure 3f).
- Measure
- EC50
- Value
- 0.239 μM
- Target
- COS-7-A*02:10
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail TCR-T cells not only recognized the NY-ESO-1 peptide presented by HLA-A*02:01 but also HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 (Section 3.2, Figure 2a).
- Measure
- qualitative
- Value
- active
- Target
- COS-7-A*02:01
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail TCR-T cells not only recognized the NY-ESO-1 peptide presented by HLA-A*02:01 but also HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 (Section 3.2, Figure 2a).
- Measure
- qualitative
- Value
- active
- Target
- COS-7-A*02:03
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail TCR-T cells not only recognized the NY-ESO-1 peptide presented by HLA-A*02:01 but also HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 (Section 3.2, Figure 2a).
- Measure
- qualitative
- Value
- active
- Target
- COS-7-A*02:05
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail TCR-T cells not only recognized the NY-ESO-1 peptide presented by HLA-A*02:01 but also HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 (Section 3.2, Figure 2a).
- Measure
- qualitative
- Value
- active
- Target
- COS-7-A*02:06
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail TCR-T cells not only recognized the NY-ESO-1 peptide presented by HLA-A*02:01 but also HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 (Section 3.2, Figure 2a).
- Measure
- qualitative
- Value
- active
- Target
- COS-7-A*02:10
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail Limited activity was observed for the NY-ESO-1 peptide with HLA-A*02:09 and HLA-A*02:11 alleles (Section 3.2, Figure 2a).
- Measure
- qualitative
- Value
- limited activity
- Target
- COS-7-A*02:09
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail Limited activity was observed for the NY-ESO-1 peptide with HLA-A*02:09 and HLA-A*02:11 alleles (Section 3.2, Figure 2a).
- Measure
- qualitative
- Value
- limited activity
- Target
- COS-7-A*02:11
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationNegative / threshold
Record detail TCR-T cells were not active for the peptides presented by HLA-A*02:07 and HLA-A*02:48 (Section 3.2, Figure 2a).
- Measure
- qualitative
- Value
- not active
- Target
- COS-7-A*02:07
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationNegative / threshold
Record detail TCR-T cells were not active for the peptides presented by HLA-A*02:07 and HLA-A*02:48 (Section 3.2, Figure 2a).
- Measure
- qualitative
- Value
- not active
- Target
- COS-7-A*02:48
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail Endogenous NY-ESO-1 peptide presented by HLA-A*02:01, HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 significantly induced TCR-T cells to secrete higher levels of IFN-γ than control T cells (Section 3.2, Figure 2b).
- Measure
- qualitative
- Value
- active
- Target
- COS-7-NY-A*02:01
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail Endogenous NY-ESO-1 peptide presented by HLA-A*02:01, HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 significantly induced TCR-T cells to secrete higher levels of IFN-γ than control T cells (Section 3.2, Figure 2b).
- Measure
- qualitative
- Value
- active
- Target
- COS-7-NY-A*02:03
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail Endogenous NY-ESO-1 peptide presented by HLA-A*02:01, HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 significantly induced TCR-T cells to secrete higher levels of IFN-γ than control T cells (Section 3.2, Figure 2b).
- Measure
- qualitative
- Value
- active
- Target
- COS-7-NY-A*02:05
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail Endogenous NY-ESO-1 peptide presented by HLA-A*02:01, HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 significantly induced TCR-T cells to secrete higher levels of IFN-γ than control T cells (Section 3.2, Figure 2b).
- Measure
- qualitative
- Value
- active
- Target
- COS-7-NY-A*02:06
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail Endogenous NY-ESO-1 peptide presented by HLA-A*02:01, HLA-A*02:03, HLA-A*02:05, HLA-A*02:06, and HLA-A*02:10 significantly induced TCR-T cells to secrete higher levels of IFN-γ than control T cells (Section 3.2, Figure 2b).
- Measure
- qualitative
- Value
- active
- Target
- COS-7-NY-A*02:10
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail TCR-T cells also exhibited activity for different HLA-A2 alleles other than HLA-A*02:01 according to ELISA (Section 3.4, Figure 4a). The activities were most potent for HLA-A*02:01, HLA-A*02:10, HLA-A*02:03, and HLA-A*02:06 but not for HLA-A*02:05.
- Measure
- qualitative
- Value
- active
- Target
- 586 mel-A*02:01
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail TCR-T cells also exhibited activity for different HLA-A2 alleles other than HLA-A*02:01 according to ELISA (Section 3.4, Figure 4a). The activities were most potent for HLA-A*02:01, HLA-A*02:10, HLA-A*02:03, and HLA-A*02:06 but not for HLA-A*02:05.
- Measure
- qualitative
- Value
- active
- Target
- 586 mel-A*02:03
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail TCR-T cells also exhibited activity for different HLA-A2 alleles other than HLA-A*02:01 according to ELISA (Section 3.4, Figure 4a). The activities were most potent for HLA-A*02:01, HLA-A*02:10, HLA-A*02:03, and HLA-A*02:06 but not for HLA-A*02:05.
- Measure
- qualitative
- Value
- active
- Target
- 586 mel-A*02:06
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail TCR-T cells also exhibited activity for different HLA-A2 alleles other than HLA-A*02:01 according to ELISA (Section 3.4, Figure 4a). The activities were most potent for HLA-A*02:01, HLA-A*02:10, HLA-A*02:03, and HLA-A*02:06 but not for HLA-A*02:05.
- Measure
- qualitative
- Value
- active
- Target
- 586 mel-A*02:10
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationNegative / threshold
Record detail The activities were most potent for HLA-A*02:01, HLA-A*02:10, HLA-A*02:03, and HLA-A*02:06 but not for HLA-A*02:05 (Section 3.4, Figure 4a).
- Measure
- qualitative
- Value
- not active
- Target
- 586 mel-A*02:05
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail 624 mel cells, which are naturally double-positive cells (HLA-A*02:01+, NY-ESO-1+), exhibited potent activity toward TCR-T cells (Section 3.4, Figure 4a).
- Measure
- qualitative
- Value
- active
- Target
- 624 mel
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationNegative / threshold
Record detail As expected, no activity was detected for the 586 mel WT strain (Section 3.4, Figure 4a).
- Measure
- qualitative
- Value
- no activity
- Target
- 586 mel WT
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail Similar to 586 mel-A2 cells, TCR-T cells exhibited activity for different HLA-A2 alleles other than HLA-A*02:01 in 5637-NY-A2 cells (Section 3.4, Supplementary Figure S4).
- Measure
- qualitative
- Value
- active
- Target
- 5637-NY-A*02:01
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail Similar to 586 mel-A2 cells, TCR-T cells exhibited activity for different HLA-A2 alleles other than HLA-A*02:01 in 5637-NY-A2 cells (Section 3.4, Supplementary Figure S4).
- Measure
- qualitative
- Value
- active
- Target
- 5637-NY-A*02:03
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail Similar to 586 mel-A2 cells, TCR-T cells exhibited activity for different HLA-A2 alleles other than HLA-A*02:01 in 5637-NY-A2 cells (Section 3.4, Supplementary Figure S4).
- Measure
- qualitative
- Value
- active
- Target
- 5637-NY-A*02:06
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationPositive observation
Record detail Similar to 586 mel-A2 cells, TCR-T cells exhibited activity for different HLA-A2 alleles other than HLA-A*02:01 in 5637-NY-A2 cells (Section 3.4, Supplementary Figure S4).
- Measure
- qualitative
- Value
- active
- Target
- 5637-NY-A*02:10
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationNegative / threshold
Record detail As expected, no activity was detected in the 586 mel-WT, 5637-WT, and 5637-NY strains (Section 3.4).
- Measure
- qualitative
- Value
- no activity
- Target
- 5637-WT
- Assay
- Not reported by source
ImmunomodulatoryT-cell activationNegative / threshold
Record detail As expected, no activity was detected in the 586 mel-WT, 5637-WT, and 5637-NY strains (Section 3.4).
- Measure
- qualitative
- Value
- no activity
- Target
- 5637-NY
- Assay
- Not reported by source
PMC12891685
19 observationsImmunomodulatoryAntibacterialPositive observation
Record detail IFNγ ELISPOT results with a median fold change with the addition of the TAA MAGE in R was 2.0-fold (Fig. 3A).
- Measure
- fold_change
- Value
- 2.0-fold
- Target
- Homo sapiens
- Assay
- Not reported by source
ImmunomodulatoryAntibacterialPositive observation
Record detail IFNγ ELISPOT results with a median fold change ... MAGE/anti-PD-1 3.0-fold (Fig. 3A).
- Measure
- fold_change
- Value
- 3.0-fold
- Target
- Homo sapiens
- Assay
- Not reported by source
ImmunomodulatoryAntibacterialPositive observation
Record detail In NR for MAGE the increase was 1.1-fold (Fig. 3B).
- Measure
- fold_change
- Value
- 1.1-fold
- Target
- Homo sapiens
- Assay
- Not reported by source
ImmunomodulatoryAntibacterialPositive observation
Record detail In NR ... MAGE/anti-PD-1 1.6-fold (Fig. 3B).
- Measure
- fold_change
- Value
- 1.6-fold
- Target
- Homo sapiens
- Assay
- Not reported by source
ImmunomodulatoryAntibacterialPositive observation
Record detail In the GrB ELISPOT we saw an increase in immune responses for MAGE ... for the R of 2.5 ... -fold (Fig. 3C).
- Measure
- fold_change
- Value
- 2.5-fold
- Target
- Homo sapiens
- Assay
- Not reported by source
ImmunomodulatoryAntibacterialPositive observation
Record detail In the GrB ELISPOT we saw an increase in immune responses for ... MAGE/anti-PD-1 for the R of ... 4.7-fold (Fig. 3C).
- Measure
- fold_change
- Value
- 4.7-fold
- Target
- Homo sapiens
- Assay
- Not reported by source
ImmunomodulatoryAntibacterialPositive observation
Record detail When considering the NR, fold change was 1.4 by MAGE stimulation (Fig. 3D).
- Measure
- fold_change
- Value
- 1.4-fold
- Target
- Homo sapiens
- Assay
- Not reported by source
ImmunomodulatoryAntibacterialPositive observation
Record detail When considering the NR, fold change was ... by MAGE and anti-PD-1 3.1 (Fig. 3D).
- Measure
- fold_change
- Value
- 3.1-fold
- Target
- Homo sapiens
- Assay
- Not reported by source
ImmunomodulatoryAntibacterialPositive observation
Record detail The increase of NY-ESO-1 to NY-ESO-1/anti-PD-1 in R was significant, with an increase of >60% in IFNγ (Fig. 3E,F).
- Measure
- fold_change
- Value
- increase of >60% in IFNγ
- Target
- Homo sapiens
- Assay
- Not reported by source
ImmunomodulatoryAntibacterialPositive observation
Record detail The increase of NY-ESO-1 to NY-ESO-1/anti-PD-1 in R was significant, with an increase of ... >100% in GrB (Fig. 3G,H).
- Measure
- fold_change
- Value
- increase of >100% in GrB
- Target
- Homo sapiens
- Assay
- Not reported by source
ImmunomodulatoryAntibacterialNegative / threshold
Record detail The IFNγ/GrB-ELISPOT results show in principle that LAG-3 has no effect either alone or in combination with anti-PD-1 (Fig. 4A).
- Measure
- fold_change
- Value
- no effect
- Target
- Homo sapiens
- Assay
- Not reported by source
ImmunomodulatoryAntibacterialNegative / threshold
Record detail The IFNγ/GrB-ELISPOT results show in principle that LAG-3 has no effect either alone or in combination with anti-PD-1 (Fig. 4A).
- Measure
- fold_change
- Value
- no effect
- Target
- Homo sapiens
- Assay
- Not reported by source
ImmunomodulatoryAntibacterialNegative / threshold
Record detail The IFNγ/GrB-ELISPOT results show in principle that LAG-3 has no effect either alone or in combination with anti-PD-1 (Fig. 4B).
- Measure
- fold_change
- Value
- no effect
- Target
- Homo sapiens
- Assay
- Not reported by source
ImmunomodulatoryAntibacterialNegative / threshold
Record detail The IFNγ/GrB-ELISPOT results show in principle that LAG-3 has no effect either alone or in combination with anti-PD-1 (Fig. 4B).
- Measure
- fold_change
- Value
- no effect
- Target
- Homo sapiens
- Assay
- Not reported by source
ImmunomodulatoryAntibacterialNegative / threshold
Record detail The same applies to TIM-3, which does not elicit an immune response either alone or in combination with anti-PD-1 (Fig. 4C).
- Measure
- fold_change
- Value
- no effect
- Target
- Homo sapiens
- Assay
- Not reported by source
ImmunomodulatoryAntibacterialNegative / threshold
Record detail The same applies to TIM-3, which does not elicit an immune response either alone or in combination with anti-PD-1 (Fig. 4C).
- Measure
- fold_change
- Value
- no effect
- Target
- Homo sapiens
- Assay
- Not reported by source
ImmunomodulatoryAntibacterialNegative / threshold
Record detail The same applies to TIM-3, which does not elicit an immune response either alone or in combination with anti-PD-1 (Fig. 4D).
- Measure
- fold_change
- Value
- no effect
- Target
- Homo sapiens
- Assay
- Not reported by source
ImmunomodulatoryAntibacterialNegative / threshold
Record detail The same applies to TIM-3, which does not elicit an immune response either alone or in combination with anti-PD-1 (Fig. 4D).
- Measure
- fold_change
- Value
- no effect
- Target
- Homo sapiens
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail The MAGE pentamer as TAA showed, as expected, lower expression of CD8+/MAGE pentamer+ cells of a mean of 0.43%, n=3 HD (Fig. 2C).
- Measure
- other
- Value
- 0.43%
- Target
- Homo sapiens
- Assay
- Not reported by source
Citation and release provenance
Cite this identity as PepDiana record PEPDIA-PLP-002699, release PepDiana-V1-20260620. Experimental observations retain their paper, mention, and activity-record identifiers.
Record updated: 2026-06-22T07:14:26.229247+00:00